Amphastar Pharmaceuticals Inc (AMPH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AMPH Annual Cash Flow →
The quarterly cash flow data below helps track how Amphastar Pharmaceuticals Inc's liquidity profile has evolved over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
3 Months
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income6.42
Depreciation & amortization8.08
Amortization of Other Assets7.03
Accretion Expense0.00
Impairment of Long-Lived Assets to be Disposed of0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories6.25
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation9.27
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Sharebased Compensation Expense Nonemployee-
Increase Decrease In Income Tax Refund Deposits And Payable7.74
Deconsolidation Gain Or Loss Amount-
Operating Lease Right Of Use Asset Amortization Expense2.14
Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments-0.42
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-4.55
Increase (Decrease) in Accounts Payable and Accrued Liabilities9.60
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.33
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.42
Discontinued operations0.00
Net Cash flow from Operating Activities47.84
Investing Activities
Capital Expenditures-9.51
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities15.50
Payments to Acquire Marketable Securities-22.80
Real Estate Investments0.00
Capitalizedlabor O H and I N T E R E S T Expenditures Incurred But Not Yet Paid-
Payments For Deposits And Other Assets0.07
Capitalized Labor Overhead And Interest On Self Constructed Assets-
Purchase Of Short Term Investments-
Payments Acquisitions Of Assets-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for Other Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-16.73
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.03
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-29.49
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments Of Deferred Issuance Costs-
Proceeds From Payments For Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Net Of Withholding Tax Payments-0.69
Acquisition Of Additional Ownership Interest In Anp-
Settlement Of Equity Awards-
Payments To Acquire Additional Ownership Interest-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-30.21
Effect of exchange rate on cash flow-0.14
Discontinued operations0.00
Free Cash Flow38.33
Total Cash Flow0.76
4 historic quarters locked

Sign in to unlock the full Amphastar Pharmaceuticals Inc cash flow history.

About Amphastar Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001297184-26-000047

Figures are derived from filed reports and may be restated. Historical data is subject to revision.